Format

Send to

Choose Destination
Trends Mol Med. 2013 Jun;19(6):355-67. doi: 10.1016/j.molmed.2013.03.005. Epub 2013 Apr 17.

CD39 and CD73 in immunity and inflammation.

Author information

1
Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.

Abstract

The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.

PMID:
23601906
PMCID:
PMC3674206
DOI:
10.1016/j.molmed.2013.03.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center